ReviewF1000Research2018
Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors.
Review in F1000Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 37 citations in OpenAlex.
- Biofabrication of pheochromocytoma and paraganglioma tumor organoids and assessment of response to systemic therapy.Scientific reports · 2025Article
- Massive paraganglioma masquerading as ovarian tumor: a unique case of paraganglioma of undetermined genetic origin.Proceedings (Baylor University. Medical Center) · 2025Article
- Molecular classification and tumor microenvironment characteristics in pheochromocytomas.eLife · 2024Article
- Tumor metabolism in pheochromocytomas: clinical and therapeutic implications.Exploration of targeted anti-tumor therapy · 2024Review
- Management of pheochromocytomas and paragangliomas: Review of current diagnosis and treatment options.Cancer medicine · 2023Review
- Whole transcriptome analysis of canine pheochromocytoma and paraganglioma.Frontiers in veterinary science · 2023Article
- Single-nuclei and bulk-tissue gene-expression analysis of pheochromocytoma and paraganglioma links disease subtypes with tumor microenvironment.Nature communications · 2022Article
- Metformin Treatment Induces Different Response in Pheochromocytoma/Paraganglioma Tumour Cells and in Primary Fibroblasts.Cancers · 2022Article
- Anticancer Efficacy and Mechanisms of a Dual Targeting of Norepinephrine Transporter and Thyrointegrin αvβ3 Antagonist in Neuroblastoma.Journal of Cancer · 2022Article
- A First Case Report of Orbital Extra-Adrenal Paraganglioma in Cat.Veterinary sciences · 2021Article
- The use of immunotherapy treatment in malignant pheochromocytomas/paragangliomas: a case report.Journal of medical case reports · 2021Article
- HIF-Prolyl Hydroxylase Domain Proteins (PHDs) in Cancer-Potential Targets for Anti-Tumor Therapy?Cancers · 2021Review
- Management and outcome of metastatic pheochromocytomas/paragangliomas: an overview.Journal of endocrinological investigation · 2021Review
- Review
- Recent advances in the management of pheochromocytoma and paraganglioma.Hypertension research : official journal of the Japanese Society of Hypertension · 2020Review
- Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma.Current treatment options in oncology · 2020Review
- Clinical implications of the oncometabolite succinate in SDHx-mutation carriers.Clinical genetics · 2020Review
- Mutational profile and genotype/phenotype correlation of non-familial pheochromocytoma and paraganglioma.Oncotarget · 2019Article
- Diagnostic efficacy of 18F-FDG PET/CT in patients with adrenal incidentaloma.Endocrine connections · 2019Article
- Malignant Pheochromocytomas/Paragangliomas and Ectopic Hormonal Secretion: A Case Series and Review of the Literature.Cancers · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inactivating mutations of the succinate dehydrogenase subunit B (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.